Treatment of Established Peritoneal Fibrosis by Gene Transfer of Smad7 in a Rat Model of Peritoneal Dialysis
Open Access
- 18 February 2009
- journal article
- Published by S. Karger AG in American Journal of Nephrology
- Vol. 30 (1) , 84-94
Abstract
Background/Aims: It has been shown that blockade of TGF-β1 signaling with Smad7 prevents experimental peritoneal fibrosis. The present study investigated whether Smad7 has a therapeutic effect on established peritoneal fibrosis associated with peritoneal dialysis (PD). Methods: A rat model of peritoneal fibrosis was induced by a daily intraperitoneal infusion of 4.25% Dianeal. After peritoneal fibrosis had been established on day 14, groups of 6 rats were treated intraperitoneally with gene transfer of Smad7 or control plasmids using an ultrasound-microbubble-mediated system for 2 weeks until day 28. In addition, a group of 6 diseased rats was euthanized on day 14 before treatment as the basal disease control. Results: Compared to the control-treatment animals on day 28, real-time PCR, Western blot, and confocal microscopy revealed that Smad7 gene transfer significantly attenuated the increased peritoneal fibrosis including the thickening of fibrotic peritoneum, accumulation of α-SMA and collagen I, and an improvement in peritoneal dysfunction (all p < 0.05). Importantly, Smad7 treatment also improved the severity of peritoneal fibrosis and functional impairment when compared to those on day 14 before treatment (all p < 0.05). Inhibition of the established peritoneal fibrosis by Smad7 was associated with an abrogation of TGF-β signaling and upregulation of TGF-β1 and PAI-1. Conclusions: Smad7 gene therapy is able to inhibit established peritoneal fibrosis in a rat model of PD. Results from this study suggest that Smad7 may be a therapeutic agent for the treatment of peritoneal fibrosis associated with PD.Keywords
This publication has 27 references indexed in Scilit:
- Smad7 as a therapeutic agent for chronic kidney diseasesFrontiers in Bioscience-Landmark, 2008
- Reduction of Perlecan Synthesis and Induction of TGF-β1 in Human Peritoneal Mesothelial Cells Due to High Dialysate Glucose ConcentrationJournal of the American Society of Nephrology, 2004
- Inhibition of Renal Fibrosis by Gene Transfer of Inducible Smad7 Using Ultrasound-Microbubble System in Rat UUO ModelJournal of the American Society of Nephrology, 2003
- Smad7 Inhibits Fibrotic Effect of TGF-β on Renal Tubular Epithelial Cells by Blocking Smad2 ActivationJournal of the American Society of Nephrology, 2002
- Blockade of the Effects of TGF-β1 on Mesangial Cells by Overexpression of Smad7Journal of the American Society of Nephrology, 2002
- Gene transfer of Smad7 using electroporation of adenovirus prevents renal fibrosis in post-obstructed kidneyKidney International, 2002
- Gene transfer of transforming growth factor-beta1 to the rat peritoneum: effects on membrane function.2001
- Effects of glucose dialysate on extracellular matrix production by human peritoneal mesothelial cells (HPMC): the role of TGF‐βNephrology Dialysis Transplantation, 2001
- Smad7 Binds to Smurf2 to Form an E3 Ubiquitin Ligase that Targets the TGFβ Receptor for DegradationMolecular Cell, 2000
- Changes of cytokine profiles during peritonitis in patients on continuous ambulatory peritoneal dialysisAmerican Journal of Kidney Diseases, 2000